Keeping shareholders in the loop, page-41

Remember when we were told that the Phase 2 results for Starpharma’s flagship in house drug DEP-Docetaxel was going to be ready in 2018?

The pom-pom club on Hotcopper then glowingly agreed for the next 5 (FIVE) years that the reason the trial kept getting extended and the results subsequently delayed until late 2023 was because the results must be SO GOOD.

Well perhaps Cheryl and the boffins at Abbotsford have now seen the Viraleze post-market study results and they are SO GOOD that the results will be kept under wraps, and new extended and enlarged trials will now be run for another few years. You know, because why release the great results now when in 2028 Starpharma could have even better results.